相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Tineke Casneuf et al.
LEUKEMIA (2021)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Homer C. Adams et al.
CYTOMETRY PART A (2019)
Longitudinal Flow Cytometry Identified Minimal Residual Disease (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
Jingli Gu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2018)
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer et al.
HAEMATOLOGICA (2018)
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions
Nicole J. Gormley et al.
JAMA ONCOLOGY (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
Sham Mailankody et al.
BLOOD ADVANCES (2017)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Taiga Nishihori et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study
Dickran Kazandjian et al.
BLOOD (2016)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Sham Mailankody et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Deep Response in Multiple Myeloma: A Critical Review
Mariateresa Fulciniti et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79
Jeroen Lammerts van Bueren et al.
BLOOD (2014)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)